KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash & Equivalents (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Cash & Equivalents data on record, last reported at $245.5 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 63.78% year-over-year to $245.5 million; the TTM value through Sep 2025 reached $245.5 million, up 63.78%, while the annual FY2024 figure was $99.5 million, 10.92% down from the prior year.
  • Cash & Equivalents reached $245.5 million in Q3 2025 per EBS's latest filing, down from $267.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $642.6 million in Q4 2022 and bottomed at $69.7 million in Q2 2024.
  • Average Cash & Equivalents over 5 years is $261.8 million, with a median of $195.4 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: crashed 82.62% in 2023, then surged 283.5% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $576.1 million in 2021, then rose by 11.54% to $642.6 million in 2022, then plummeted by 82.62% to $111.7 million in 2023, then decreased by 10.92% to $99.5 million in 2024, then skyrocketed by 146.73% to $245.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $245.5 million in Q3 2025, $267.3 million in Q2 2025, and $149.1 million in Q1 2025.